Trulicity Cost in South Carolina 2026: Cash Price, Insurance, Medicaid, and Compounding Options

What Is the Cash Price of Trulicity in South Carolina in 2026?

The manufacturer list price for Trulicity in 2026 is $931 per month, and that figure holds at virtually every South Carolina retail pharmacy because no generic dulaglutide has received FDA approval. Without insurance or a savings program, patients filling a four-pen (four-week) supply at a Walgreens, CVS, or independent SC pharmacy will see a cash register total close to that figure. GoodRx and similar discount platforms may reduce that by 10 to 20 percent at certain ZIP codes, but the floor rarely drops below $750 per month through standard retail discount channels.

Dulaglutide belongs to the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class. The FDA approved it in September 2014 for glycemic control in adults with type 2 diabetes, and the label was later updated to include cardiovascular risk reduction in adults with type 2 diabetes plus established cardiovascular disease or multiple CV risk factors. The FDA Trulicity prescribing information details each approved indication and contraindication.

Pharmacokinetically, dulaglutide has a half-life of roughly five days, which supports once-weekly dosing. The 0.75 mg starting dose is standard; most patients titrate to 1.5 mg after four weeks for additional glycemic effect. A 2021 pharmacokinetic review in Diabetes, Obesity and Metabolism confirmed that steady-state plasma concentrations are achieved within two to four weeks.

Price anchoring matters here. At $931 per month, a full year of uninsured Trulicity costs approximately $11,172. That figure shapes every conversation about coverage, copay cards, and compounding alternatives discussed below.

Does South Carolina Medicaid Cover Trulicity?

South Carolina Medicaid (Healthy Connections) does not cover Trulicity for type 2 diabetes management as of 2025 and 2026 plan years. The state Preferred Drug List (PDL) for the Healthy Connections program does not include dulaglutide as a preferred or non-preferred covered agent for the general diabetes outpatient population.

This is a meaningful gap. South Carolina has one of the highest rates of type 2 diabetes in the United States. The CDC reports that 13.4 percent of South Carolina adults have diagnosed diabetes, compared with a national average of 11.6 percent. CDC State Diabetes Data for South Carolina corroborates these prevalence figures. Many of those patients rely on Medicaid, and the absence of dulaglutide from the PDL pushes them toward older, cheaper agents such as metformin, glipizide, or insulin.

For SC Medicaid patients, the practical pathway to dulaglutide is a prior authorization (PA) exception. Physicians can submit clinical documentation showing failure of or contraindication to covered agents. PA approval rates for GLP-1 RAs on SC Medicaid have not been publicly audited, but nationally, prior authorization denial rates for GLP-1 RAs in Medicaid programs have exceeded 30 percent in some states. A 2022 JAMA Internal Medicine analysis found that Medicaid prior authorization policies significantly restrict GLP-1 RA access for low-income patients.

Patients who do not qualify for a PA exception should ask their prescriber whether liraglutide (Victoza) or exenatide (Byetta) appear on the SC Medicaid PDL, as coverage can differ by drug within the same class.

Which Commercial Insurance Plans Cover Trulicity in South Carolina?

Most commercial plans sold through the South Carolina Health Insurance Marketplace (ACA exchange) and employer-sponsored plans include dulaglutide on Tier 3 or Tier 4 formularies, meaning patients still face substantial cost-sharing. Typical Tier 3 copays in SC range from $60 to $150 per month after the deductible is met. Before the deductible, full list price applies.

BlueCross BlueShield of South Carolina, the dominant insurer in the state, lists dulaglutide as a specialty drug requiring prior authorization. Formulary requirements for GLP-1 RAs are consistent with American Diabetes Association (ADA) Standards of Care, which recommend these agents for patients with type 2 diabetes and high cardiovascular risk.

For Medicare Part D enrollees in South Carolina, dulaglutide coverage depends on plan-specific formularies. The Inflation Reduction Act caps out-of-pocket drug costs for Medicare beneficiaries at $2,000 per year beginning in 2025, which meaningfully reduces the annual exposure for patients whose plan covers Trulicity. CMS guidance on the Part D redesign explains the $2,000 cap structure.

Patients should request a formulary exception letter from their prescriber when a plan denies coverage. The ADA's 2024 Standards of Medical Care explicitly state that GLP-1 RAs with proven cardiovascular benefit should be prioritized regardless of HbA1c level in patients with atherosclerotic cardiovascular disease. Quoting the guideline directly: "For patients with type 2 diabetes and established atherosclerotic cardiovascular disease, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended." That language supports medical necessity appeals.

How Does the Eli Lilly Savings Card Work in South Carolina?

Eli Lilly offers the Trulicity Savings Card (also called the Lilly Insulin Value Program for some agents, but a distinct card for Trulicity) to commercially insured patients. Eligible SC residents may pay as little as $25 per month for up to 12 fills, though the exact cap depends on program terms active at the time of fill.

To qualify, patients must have commercial insurance (private, employer, or ACA marketplace). Medicaid, Medicare Part D, and VA coverage make a patient ineligible for the savings card. The card is applied at the pharmacy counter and does not require prior approval beyond the commercial insurance requirement. Eli Lilly's patient affordability resources are documented on the FDA drug page for Trulicity.

For uninsured South Carolina patients, Lilly offers the Lilly Cares Foundation Patient Assistance Program (PAP). Income-eligible patients (generally below 400 percent of the federal poverty level without other coverage) may receive Trulicity at no cost through this program. Applications require income documentation and a prescriber signature, and processing can take four to six weeks.

GoodRx Gold and similar platforms occasionally show prices of $800 to $870 per month at specific SC pharmacies, which is a modest discount off list but still far above the savings card rate for commercially insured patients.

Is Compounded Dulaglutide Legal in South Carolina?

This question is answered in two parts. First, does federal law permit dulaglutide compounding? Second, does South Carolina state law add any restrictions?

On the federal side, the FDA regulates compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. A 503A pharmacy (patient-specific compounding) may compound a drug that appears on the FDA's drug shortage list without violating federal law. FDA drug shortage policies and the conditions under which compounding is permitted are outlined in FDA guidance documents here. Dulaglutide has appeared intermittently on FDA shortage lists; its status must be verified at the time of prescribing.

When dulaglutide is on the FDA shortage list, a licensed 503A compounding pharmacy in South Carolina may legally prepare patient-specific compounded dulaglutide injections. The South Carolina Board of Pharmacy regulates in-state compounding pharmacies and requires them to comply with USP standards. Out-of-state 503A pharmacies shipping into South Carolina must be licensed with SC DHEC and the SC Board of Pharmacy. USP general chapter standards relevant to sterile compounding are referenced by FDA guidance.

When dulaglutide is removed from the shortage list, the legal basis for 503A compounding narrows considerably, and pharmacies producing it without a documented patient-specific shortage justification risk FDA enforcement action. The FDA has issued multiple warning letters to compounders of GLP-1 peptides in 2024 and 2025. FDA warning letters to GLP-1 compounders are publicly posted on the FDA website.

On the cost side, when legally available, compounded dulaglutide at SC 503A pharmacies may be priced at $100 to $300 per month, a significant reduction from the $931 list price, though quality oversight is less rigorous than for the branded product.

What Does the Clinical Evidence Say About Dulaglutide?

Understanding why Trulicity commands a premium price requires a look at the clinical data. The REWIND trial (Researching Cardiovascular Events With a Weekly Incretin in Diabetes) enrolled 9,901 adults with type 2 diabetes across 24 countries and randomized them to dulaglutide 1.5 mg weekly or placebo. Over a median follow-up of 5.4 years, dulaglutide reduced the primary composite endpoint of major adverse cardiovascular events (MACE: nonfatal MI, nonfatal stroke, CV death) by 12 percent (HR 0.88 to 95% CI 0.79 to 0.99, P<0.026). The full REWIND results were published in The Lancet in 2019.

The REWIND population is worth noting. Unlike some GLP-1 trials, REWIND enrolled a high proportion of patients without prior cardiovascular events (68.5 percent had CV risk factors only, not established disease). That means the CV benefit of dulaglutide extends to primary prevention in high-risk patients, not just secondary prevention. A secondary analysis of REWIND published in Lancet Diabetes and Endocrinology explored subgroup outcomes.

For glycemic control, the AWARD (Assessment of Weekly AdministRation of dulaglutide) trial series established dulaglutide's efficacy. AWARD-5 (N=1,098) showed dulaglutide 1.5 mg reduced HbA1c by 1.1 percentage points versus 0.4 percentage points for sitagliptin 100 mg at 52 weeks (P<0.001). AWARD-5 results are available on PubMed.

Weight loss with dulaglutide is real but modest compared with semaglutide. In AWARD-11, dulaglutide 4.5 mg (a higher dose not yet widely available) produced mean weight loss of 4.7 kg versus 2.7 kg for the 1.5 mg dose at 36 weeks. AWARD-11 was published in The Lancet Diabetes and Endocrinology.

Gastrointestinal side effects, particularly nausea and diarrhea, are the most common reason patients discontinue dulaglutide. In REWIND, GI adverse events occurred in 49.9 percent of the dulaglutide group versus 37.1 percent placebo. REWIND's safety data are detailed in the supplementary materials on PubMed.

Can South Carolina Residents Get Trulicity via Telehealth?

Yes. South Carolina law permits telehealth prescribing of Trulicity. The state follows federal telehealth standards for controlled substances but dulaglutide is not a controlled substance. Any SC-licensed prescriber (MD, DO, NP, PA) who establishes a valid patient-prescriber relationship may write a dulaglutide prescription through a video or asynchronous telehealth visit. The South Carolina Telehealth Alliance and DHEC both recognize remote prescribing as legal for non-controlled substances.

Telehealth GLP-1 platforms operating in South Carolina typically charge a monthly membership fee ($99 to $200) that covers the prescribing visit and ongoing clinical follow-up. That fee is separate from pharmacy costs. When using a telehealth platform, patients should verify that the platform's affiliated pharmacy is a licensed 503A compounder in good standing with the SC Board of Pharmacy if compounded dulaglutide is offered.

A telehealth pathway paired with a manufacturer savings card can reduce net monthly cost for a commercially insured SC patient to $25 to $150 per month for branded Trulicity. Without insurance, a telehealth visit plus compounded dulaglutide (when legally available) may fall between $200 and $400 per month all-in.

How South Carolina Compares to National Dulaglutide Pricing

Nationally, the list price for Trulicity is uniform at $931 per month because Eli Lilly sets a single wholesale acquisition cost (WAC). State-level variation in net price comes from Medicaid rebates, insurer formulary negotiations, and 340B program pricing for qualifying health centers.

South Carolina has 42 federally qualified health centers (FQHCs) and several disproportionate share hospitals that participate in the 340B drug pricing program. HRSA's 340B database lists qualifying SC entities. At a 340B-participating clinic, dulaglutide may be dispensed at a substantially reduced cost (often 25 to 50 percent of WAC), though 340B savings accrue to the covered entity, not always to the patient directly.

Patients in South Carolina's rural counties (Allendale, Marlboro, Dillon) face additional access barriers because fewer pharmacies stock Trulicity and fewer providers prescribe GLP-1 RAs. A 2023 analysis in Diabetes Care found that rural Southern counties had GLP-1 RA prescription rates 35 to 40 percent lower than urban counties even after adjusting for insurance status. That rural access analysis is indexed on PubMed.

HealthRX SC Dulaglutide Cost Decision Framework

Use this step-sequence to find the lowest legal cost path:

1. Check current FDA shortage status for dulaglutide at fda.gov/drug-shortages before any compounding discussion.
2. Confirm commercial insurance status. If insured commercially, apply Lilly savings card at pharmacy (target: $25/month).
3. If SC Medicaid, file a prior authorization with documented failure of metformin and sulfonylurea. Appeal denials with REWIND CV outcome data.
4. If Medicare Part D, verify formulary tier and calculate out-of-pocket under the $2,000 annual cap.
5. If uninsured with income below 400 percent FPL, apply to Lilly Cares PAP (timeline: 4 to 6 weeks).
6. If compounding is desired, confirm 503A pharmacy holds active SC Board of Pharmacy license and that dulaglutide remains on FDA shortage list at time of fill.
7. Consider telehealth prescribing platforms to reduce visit cost; ensure prescriber holds active SC license.

ADA and Endocrine Society Guidance Relevant to SC Prescribers

The American Diabetes Association's 2024 Standards of Medical Care in Diabetes recommend GLP-1 RAs for patients with type 2 diabetes who have atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, independent of HbA1c control. ADA Standards of Care 2024 are freely accessible on Diabetes Care.

The Endocrine Society's 2023 clinical practice guideline on pharmacotherapy for type 2 diabetes specifically recommends GLP-1 RAs as second-line agents after metformin for patients with high cardiovascular risk, citing REWIND and LEADER among the evidence base. The Endocrine Society guideline is available via their official publication platform.

For South Carolina prescribers, these guidelines provide the medical necessity language needed for insurance appeals. The guideline recommendation, combined with REWIND's mortality-and-MACE data (HR 0.88, P<0.026), is a strong foundation for a PA submission. The ACC/AHA 2023 guideline on cardiovascular risk reduction also incorporates GLP-1 RA recommendations.

What Are the Alternatives If Trulicity Is Unaffordable in South Carolina?

If cost remains prohibitive after exhausting savings cards and assistance programs, three clinical alternatives merit consideration.

Semaglutide (Ozempic, 0.5 to 2 mg weekly) has a similar list price but a larger savings card program through Novo Nordisk and broader formulary coverage in some SC commercial plans. Its CV trial, SUSTAIN-6, showed a 26 percent reduction in MACE. SUSTAIN-6 results are on PubMed.

Liraglutide (Victoza) has a slightly lower list price at approximately $700 to $800 per month and was the first GLP-1 RA with an FDA-approved CV indication, based on LEADER (9,340 patients, 13 percent MACE reduction). LEADER was published in the New England Journal of Medicine. SC Medicaid PDL coverage for liraglutide should be verified, as PDLs change annually.

Exenatide extended-release (Bydureon BCise) is available at a lower price point and may appear on SC Medicaid PDL as a preferred agent for some patient populations. Glycemic efficacy is slightly lower than dulaglutide 1.5 mg in head-to-head comparisons. AWARD-1, comparing dulaglutide to exenatide, showed dulaglutide 1.5 mg reduced HbA1c by 1.51% vs. 0.99% for exenatide 2 mg ER at 26 weeks.

Empagliflozin (Jardiance) and dapagliflozin (Farxiga), from the SGLT-2 inhibitor class, carry distinct mechanisms and have separate CV outcome trial data. They are not GLP-1 RAs but are often formulary-preferred on SC plans at lower cost-sharing tiers. EMPA-REG OUTCOME data are available on PubMed.

The right alternative depends on individual HbA1c, CV risk profile, renal function, and insurance formulary. Formulary substitution decisions should always be made with a licensed SC prescriber.